News archive
Showing 665 results
May 2014
-
Media Release
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
Pivotal data in ALK+ NSCLC for Zykadia™; recently approved by US FDA, marking fastest oncology approval under Breakthrough Therapy designationFirst presentation of pivotal data from Phase III trial… -
Media Release
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
-
Media Release
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
Acromegaly, an endocrine disorder resulting from elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, is associated with high mortality(1,2)Phase III data show patients on… -
Media Release
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
March 2014
-
Media Release
Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2)- Patients reported high satisfaction with self-administration of secukinumab pre-filled syringe or… -
Media Release
Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
-
Media Release
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years- Xolair® is approved for CIU patients age… -
Media Release
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
January 2014
-
Media Release
Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
Patient safety and well-being are highest priority at Novartis Pharmaceuticals Corporation (NPC) Patient adherence activities provide important education and support to help patients… -
Media Release
Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
December 2013
-
Media Release
Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
-- Data at ASH show increased scientific understanding of CTL019 and its potential role in the treatment of certain types of lymphocytic leukemia(1,2,3,4)-- Presentations include findings that 19 of… -
Media Release
Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia